Viridian Therapeutics June 2021 Cautionary note regarding forward-looking statements This presentation contains forward-looking statements relating to Viridian Therapeutics, Inc., including statements about our plans to obtain funding, develop and commercialize our therapeutic candidates, our planned clinical trials, the timing of and our ability to obtain and maintain regulatory approvals for our therapeutic candidates, the clinical utility of our therapeutic candidates and our intellectual property positi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or Delaware 47-1187261 6200 Lookout Road, Boulder, CO 80301 (Address, including zip code, of principal executive offices) (720) 643-5200 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: ☐ TRANSITION REPORT PURSUANT TO S ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36483 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporatio ...

Table of Contents or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 Commission File No. 001-36483 MIRAGEN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 47-1187261 ( ...

miRagen Therapeutics, Inc. (MGEN) Q2 2020 Earnings Conference Call August 5, 2020 4:30 PM ET Company Participants Dan Ferry – Managing Director-LifeSci Advisors Bill Marshall – President and Chief Executive Officer Diana Escolar – Chief Medical Officer Jason Leverone – Chief Financial Officer Conference Call Participants Jonathan Miller – Evercore ISI Andreas Argyrides – Wedbush Securities Trevor Allred – Oppenheimer Operator Greetings, and welcome to the miRagen Therapeutics Q2 2020 Earnings Conference Cal ...

Revenue and Expenses - Revenue decreased to $0.2 million during the three months ended June 30, 2020, from $2.5 million during the same period in 2019, primarily due to reduced research and development activities reimbursable by Servier[167]. - Research and development expenses were $3.8 million for the three months ended June 30, 2020, down from $8.6 million in the same period in 2019, reflecting a $4.8 million decrease attributed to reduced clinical activities[168]. - General and administrative expenses were $2.7 million for the three months ended June 30, 2020, compared to $2.9 million in the same period in 2019, mainly due to decreased personnel-related costs[169]. - For the six months ended June 30, 2020, revenue was $1.0 million, down from $2.9 million in the same period in 2019, again primarily due to decreased reimbursable research and development activities[171]. - Research and development expenses for the six months ended June 30, 2020, were $9.9 million, compared to $17.4 million in the same period in 2019, a decrease of $7.5 million attributed to reduced clinical and manufacturing activities[173]. - General and administrative expenses for the six months ended June 30, 2020, were $5.4 million, down from $6.2 million in the same period in 2019, primarily due to decreased personnel-related costs[174]. Cash Flow and Financial Position - As of June 30, 2020, the company had $30.6 million in cash and cash equivalents, expected to fund operations into Q3 2021[175]. - Net cash used in operating activities was $15.2 million for the six months ended June 30, 2020, a decrease of $3.8 million compared to the same period in 2019[188]. - Net cash provided by investing activities was $2.0 million for the six months ended June 30, 2020, down from $10.2 million in the same period in 2019[189]. - Net cash provided by financing activities was $19.0 million for the six months ended June 30, 2020, compared to $0.2 million in the same period in 2019[190]. - The company generated an accumulated deficit of $182.7 million since inception, primarily due to research and development expenses[181]. Restructuring and Operational Changes - The company implemented a cost restructuring plan in August 2019, eliminating approximately 44 positions, or 50% of its workforce[186]. - Cumulative restructuring expenses recorded through June 30, 2020, amounted to approximately $2.3 million, with an expected additional $0.1 million[186]. - The company expects to incur significant expenses and increased operating losses for several years as it continues clinical development[183]. Product Development and Clinical Trials - Cobomarsen is currently being evaluated for the treatment of patients with miR-155 elevated hematological malignancies, including CTCL and ATLL[148]. - MRG-229 is a miR-29 mimic being developed for the treatment of pathological fibrosis, with preclinical data showing efficacy in various fibrotic conditions[149]. - The company plans to meet with the FDA to discuss the development path for cobomarsen in ATLL before the end of 2020[149]. - The company anticipates that research and development expenses may increase in the foreseeable future as it continues ongoing clinical trials and initiates new ones[159]. - The company has not generated any revenue from product sales and has no products approved for commercial sale[181]. Impact of COVID-19 - The COVID-19 pandemic may adversely affect the company's liquidity and operational results, impacting clinical trial enrollments and financing capabilities[180].

Restoring Biological Harmony for Patients with Debilitating Disease 1 miRagen Therapeutics NASDAQ: MGEN Jefferies Virtual Healthcare Conference June 2 – June 4, 2020 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements relating to Miragen Therapeutics, Inc., including statements about our plans to obtain funding, develop and commercialize our therapeutic candidates, our planned clinical trials, the timing of and our ability to obtain and maintain regulat ...

Miragen Therapeutics, Inc. (MGEN) Q1 2020 Earnings Conference Call May 7, 2020 4:30 PM ET Company Participants Dan Ferry - Managing Director of LifeSci Advisors Bill Marshall - President & Chief Executive Officer Jason Leverone - Chief Financial Officer Conference Call Participants Liana Moussatos - Wedbush Securities Leland Gershell - Oppenheimer Jonathan Miller - Evercore ISI Operator Greetings and welcome to the Miragen Therapeutics First Quarter 2020 Earnings Conference Call. At this time, all participa ...

Revenue and Financial Performance - Revenue for the three months ended March 31, 2020, was $0.8 million, an increase from $0.4 million in the same period of 2019, primarily due to a $0.1 million increase in grant revenue and a $0.3 million increase in reimbursable research and development activities under the Servier Collaboration Agreement[188][189] - The net loss for the three months ended March 31, 2020, was $8.0 million, compared to a net loss of $11.6 million for the same period in 2019[188] - Net cash used in operating activities was $8.5 million for the three months ended March 31, 2020, a decrease of $3.3 million compared to $11.8 million in the same period of 2019[204] - Net cash provided by investing activities was $2.0 million for the three months ended March 31, 2020, compared to a net cash outflow of $2.8 million in the same period of 2019[205] - Net cash provided by financing activities was $17.7 million for the three months ended March 31, 2020, significantly higher than $0.2 million in the same period of 2019[206] - As of March 31, 2020, the company had $36.1 million in cash and cash equivalents, which is expected to fund operations into the third quarter of 2021[192] - The company generated an accumulated deficit of $176.2 million through March 31, 2020, with substantial operating losses primarily from research and development expenses[198] Expenses - Research and development expenses for the three months ended March 31, 2020, were $6.1 million, a decrease from $8.8 million in the same period of 2019[188] - General and administrative expenses for the three months ended March 31, 2020, were $2.7 million, down from $3.4 million in the same period of 2019[188] - Research and development expenses decreased to $6.1 million for the three months ended March 31, 2020, down from $8.8 million in the same period of 2019, a reduction of approximately 30.7%[190] - General and administrative expenses were $2.7 million for the three months ended March 31, 2020, compared to $3.4 million in the same period of 2019, reflecting a decrease of about 20.6%[191] Clinical Development and Research - Cobomarsen is being developed for the treatment of patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, with ongoing clinical trials impacted by the COVID-19 pandemic[171] - MRG-110 has shown potential in increasing angiogenesis and is being evaluated for heart failure and wound healing applications, with data from Phase 1 trials indicating safety and tolerability[175] - Remlarsen is being evaluated for ocular fibrotic indications, with preclinical studies showing faster healing of corneal injuries[174] - MRG-229 is focused on idiopathic pulmonary fibrosis, with ongoing preclinical studies supported by a grant from the NIH and Yale University[178] - The company anticipates an increase in research and development expenses as it continues clinical trials and preclinical research programs[182] - The company expects to incur significant expenses and increased operating losses for at least the next several years as it continues clinical development and seeks regulatory approval for its product candidates[200] Impact of COVID-19 - The COVID-19 pandemic may adversely affect the company's liquidity and results of operations, with potential delays in clinical trials and financing[197] Cost Restructuring - The company began implementing a cost restructuring plan in August 2019, identifying approximately 44 positions for elimination, or about 50% of its workforce[202] Future Revenue Expectations - Future revenue generation is expected to fluctuate based on the timing of achieving clinical and regulatory milestones, as well as the success of product commercialization[179]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________ FORM 10-K ____________________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36483 _____________________________________ ...